VERTEX PHARMACEUTICALS INC / MA Proceeds from Stock Options Exercised
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Proceeds from Stock Options Exercised of $55.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2026-02-13
- VERTEX PHARMACEUTICALS INC / MA proceeds from stock options exercised for fiscal 2025 was $55.60M, a 11.20% increase from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA proceeds from stock options exercised for fiscal 2024 was $50.00M, a 38.12% decline from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA proceeds from stock options exercised for fiscal 2023 was $80.80M, a 44.12% decline from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA proceeds from stock options exercised for fiscal 2022 was $144.60M, a 125.23% increase from fiscal 2021.
| Period end | Proceeds from Stock Options Exercised 12 month |
|---|---|
| 2025-12-31 | $55.60M 10-K · filed 2026-02-13 |
| 2024-12-31 | $50.00M 10-K · filed 2026-02-13 |
| 2023-12-31 | $80.80M 10-K · filed 2026-02-13 |
| 2022-12-31 | $144.60M 10-K · filed 2025-02-13 |
| 2021-12-31 | $64.20M 10-K · filed 2024-02-15 |
| 2020-12-31 | $228.20M 10-K · filed 2023-02-10 |
| 2019-12-31 | $317.80M 10-K · filed 2022-02-09 |
| 2018-12-31 | $263.40M 10-K · filed 2021-02-11 |
| 2017-12-31 | $323.30M 10-K · filed 2020-02-13 |
| 2016-12-31 | $48.50M 10-K · filed 2019-02-13 |
| 2015-12-31 | $165.60M 10-K · filed 2018-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |